A clinical-stage biotechnology company focused on developing targeted therapies for cancer and other serious diseases, with its lead programs aimed at inhibiting the GAS6/AXL signaling pathway linked to tumor growth and metastasis. The company’s pipeline has centered on batiraxcept, an investigation...
1 member of Congress has disclosed 1 trade in Aravive, Inc. (ARAV), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-12-28 | BOB GIBBS | sell | $158+ |